CNMD Stock Chart & Stats
$720.00
$0.00(0.00%)
At close: 4:00 PM EDT
$720.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$625.41 - $1,135.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$24.41B
Enterprise Value$1.78K
Total Cash (Recent Filing)$37.33M
Total Debt (Recent Filing)$834.25M
Price to Earnings (P/E)25.0
Beta-0.27
Next Earnings
Oct 28, 2026EPS Estimate
17.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.85
Shares Outstanding29,951,248
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.22
Price to Sales (P/S)0.92
P/FCF Ratio8.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$785.14Price Target Upside9.05% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)75.72
Revenue Forecast (FY)$23.75B
Bulls Say, Bears Say
Bulls Say
Installed Base & Recurring ConsumablesA >10,000 AirSeal installed base creates a durable annuity stream from single‑use consumables and accessories tied to procedures. Low U.S. penetration versus a ~3M procedure TAM implies multi-year install and consumable upside, supporting recurring revenue and gross margin stability.
Healthy Gross MarginsSustained gross margins near the mid‑50s reflect advantaged product mix, pricing and platform economics across electrosurgery, smoke evacuation and orthopedics. High gross margin provides structural cushion to absorb SG&A and R&D investment while supporting consistent free cash flow generation.
Balance‑sheet De‑risking (convertible Repurchase)Retiring a large portion of convertibles meaningfully reduces potential equity dilution and simplifies capital structure. Taking this step ahead of maturity lowers refinancing uncertainty and interest variability, improving long‑run financial flexibility for M&A, buybacks and reinvestment.
Bears Say
Compressed ProfitabilityNet margin deterioration from 2024 levels suggests weaker operating leverage, likely from cost pressure, mix shifts or non‑recurring items. Persistently thin margins would reduce retained earnings, limit reinvestment capacity and constrain long‑term return on equity absent margin recovery.
Modest Cash‑flow Coverage & Working Capital SwingsOCF coverage of debt below 0.5x and variability in free cash flow reflect working‑capital swings and seasonality. Limited cash flow cushion restricts debt paydown speed and raises vulnerability to slower procedure volumes or higher interest, reducing strategic optionality over time.
Refinancing Increases Interest Burden & LeveragePlanned refinancing and elevated leverage (~3x) increase fixed financing costs and pressure on adjusted EPS and free cash flow. Higher interest expense and tighter covenant headroom can constrain M&A, R&D or buybacks and amplify downside in an operational slowdown.
Conmed News
CNMD FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was $625.41 and its highest was $1135.06 in the past 12 months.
What is Conmed’s market cap?
Conmed’s market cap is $24.41B.
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is Oct 28, 2026 which is in 88 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Jul 29, 2026. The company reported $23.945 earnings per share for the quarter, beating the consensus estimate of $19.26 by $4.685.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Undervalued.
Does Conmed pay dividends?
Conmed does not currently pay dividends.
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is 17.4.
How many shares outstanding does Conmed have?
Conmed has 29,951,248 shares outstanding.
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of $23.945 in its last earnings report, beating expectations of $19.26. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Conmed?
Currently, no hedge funds are holding shares in MX:CNMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Conmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$785.14 (9.05% Upside)
$785.14 (9.05% Upside)
Blogger Sentiment
Bullish
MX:CNMD Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.12%
12-Months-Change
Fundamentals
Return on Equity
2.44%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Company Description
Conmed
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
CNMD Company Deck
CNMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive view: near‑term headwinds included modest revenue declines on a reported basis, lower adjusted net income and EPS, weaker cash from operations and higher working capital as inventory was intentionally built. Offsetting these concerns were upgraded organic revenue guidance (5.0%–6.5%), clear momentum in core growth platforms (AirSeal, Buffalo Filter direct smoke, BioBrace), improved gross margin (up 100 bps) and maintained full‑year adjusted EPS guidance despite a planned refinancing headwind. Management also completed GI divestitures to focus resources and continued buybacks. Overall the transcript shows cautious optimism with tangible operational and strategic progress balanced against short‑term financial pressures.View all MX:CNMD earnings summariesCNMD Stock 12 Month Forecast
Average Price Target
$785.14
▲(9.05% Upside)